August 3 (SeeNews) - Israeli-based Teva Pharmaceutical Industries said it has completed the acquisition of Actavis Generics, the generic drug business of Ireland-based Allergan.
Under the deal, which was first announced in July last year, Allergan received $33.43 billion (29.82 billion euro) in cash and approximately 100 million Teva shares, Teva said in a statement late on Tuesday.
You can subscribe to our M&A newsletter here
In southeast Europe, Actavis Generics owns drug manufacturing facilities in Bulgaria, Serbia and Romania, and has representative offices in Albania, Kosovo, and Macedonia.
In Bulgaria, Teva now has two manufacturing sites employing some 2,000 people - in the towns of Dupnitsa, in southwestern Bulgaria, and in Troyan, in the northcentral part of the country.
Its Romanian unit produces, develops and markets oncology generics. The company has a drug plant in the capital Bucharest. Oncological products manufactured in Romania are present on more than 60 markets around the world, including the US and Japan, Australia, UK, France, Germany, Austria, Switzerland, Russia, Poland and others.
Zdravlje Actavis is one of the largest generic pharmaceutical companies in Serbia and a manufacturer of drugs for gastroenterology and cardiology for more than 50 years. Based in Leskovac, in southern Serbia, the facility offers a portfolio of mainly solid oral dosages, as well as modern generic products transferred from Actavis’ broad portfolio.
(1 euro=$1.1209)